Khaoula Elcadi

Ms. Khaoula Elcadi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2025 in NeuroSci
Verified
Journal Article
Open access
PDF file
KEKhaoula Elcadi
Khaoula Elcadi
RKRaymond Klevor
Raymond Klevor
NLNissrine Louhab
Nissrine Louhab
NKNajib Kissani
Najib Kissani
MCMohamed Chraa
Mohamed Chraa
Patients with Parkinson’s disease frequently suffer from complicated anxiety disorders that are entwined with their attitudes and behaviors. In regard to this population, cognitive behavioral therapy (CBT) has been attracting an increasing amount of attention as a potentially effective treatment for mental health issues like anxiety. CBT helps patients manage stress and improve their psychological well being through behavioral, relaxation, and cognitive techniques. Even though there is already evidence that cognitive behavioral therapy (CBT) can dramatically reduce psychological symptoms in Parkinson’s patients, more thorough research is required to determine its exact role in comprehensive anxiety treatment and prove its long-term efficacy. The purpose of this study is to examine the body of research on the use of cognitive behavioral therapy (CBT) to treat anxiety in patients with Parkinson’s disease, looking at its limitations and challenges as well as clinical characteristics, advantages, and possible behavioral and psychological impacts.

6 November 2025 in Diseases
Verified
Journal Article
Open access
PDF file
KEKhaoula Elcadi
Khaoula Elcadi
OROussama Cherkaoui Rhazouani
Oussama Cherkaoui Rhazouani
NLNissrine Louhab
Nissrine Louhab
NKNajib Kissani
Najib Kissani
MCMohamed Chraa
Mohamed Chraa
Background/Objectives: An individual’s quality of life is greatly impacted by the motor and non-motor symptoms of Parkinson’s disease (PD), which include anxiety and depression. Using the Hospital Anxiety and Depression Scale (HADS), this study sought to determine the prevalence of anxiety and depression in Moroccan patients with Parkinson’s disease (PD) and investigate any possible associations with clinical characteristics and pharmacological treatment. Methods: The HADS was used to assess 100 PD patients in total. Clinical and demographic information, including prescription drug use, was gathered. The relationships between HADS scores and clinical factors were evaluated using Pearson’s correlation. Results: According to the HADS assessment, 20% of respondents had no anxiety symptoms, 17% had borderline symptoms, and 63% of patients reported definite anxiety symptoms. Of those with depression, 24% showed no symptoms, 14% were borderline, and 62% were certain. The average HADS-A and HADS-D scores were 2.34 and 2.43, respectively. L-DOPA alone was used to treat half of the patients, while combinations of Trivastal, Sifrol, anticholinergics, or antidepressants were given to the other half. There were no discernible correlations between HADS scores and clinical or demographic traits. Conclusions: The HADS is a useful instrument for assessing anxiety and depression in PD patients. Regardless of the method of treatment or stage of the disease, psychiatric symptoms are prevalent. For PD patients to benefit from early interventions and achieve an improved quality of life, routine screening is crucial.

25 June 2025 in Psychiatry International
Verified
Journal Article
Open access
PDF file
KEKhaoula Elcadi
Khaoula Elcadi
Yahya NajiYahya Naji
Yahya Naji
RKRaymond Klevor
Raymond Klevor
NLNissrine Louhab
Nissrine Louhab
NKNajib Kissani
Najib Kissani
MCMohamed Chraa
Mohamed Chraa
Psychotherapy has become a necessity for Parkinson’s patients suffering from anxiety disorder. There are different types of therapy; for example, Morita therapy, first proposed in 1919, is a psychological therapy. It is mainly used as an alternative therapy in Asian countries such as Japan and China. Morita therapy focuses on accepting emotions, including anxiety, rather than trying to reduce them. Although it has had an impact on treating anxiety disorder in other populations, there have been no studies to date investigating the evidence and effects of Morita therapy on anxiety disorder in Parkinson’s patients. This opinion article focuses on conducting a literature review to identify relevant studies on the applications of Morita therapy in anxiety disorders and explore the possibility of proposing it as a treatment option for Parkinson’s patients.

15 September 2026 in Diseases
Verified
Journal Article
Open access
PDF file
KEKhaoula Elcadi
Khaoula Elcadi
OROussama Cherkaoui Rhazouani
Oussama Cherkaoui Rhazouani
NLNissrine Louhab
Nissrine Louhab
NKNajib Kissani
Najib Kissani
MCMohamed Chraa
Mohamed Chraa
Background: In Parkinson’s disease (PD), non-motor symptoms especially anxiety represent a significant and underappreciated burden. Despite the lack of particular validation in this demographic, the Hamilton Anxiety Rating Scale (HAM-A) is widely used in clinical and research contexts. Methods: A cross-sectional study of 200 Parkinson’s disease patients (mean age 62.77 ± 8.32 years; 118 men and 82 females) was conducted. The Hoehn & Yahr (H&Y) scale was used to grade motor severity, whereas the HAM-A was used to measure anxiety. Results: Of the patients, 52.5% of people (n = 105; mean score 13.85 ± 6.09) had anxiety (HAM-A ≥ 14). Age (r = 0.032; p = 0.657), disease duration (r = 0.115; p = 0.105), H&Y stage (r = −0.073; p = 0.305), and sex (p = 0.856) did not significantly correlate with the HAM-A score. Conclusion: Although the HAM-A shows a high incidence of anxiety in Parkinson’s disease (PD), its consistent lack of connection with clinical illness markers raises serious concerns about construct validity, which are probably caused by somatic item overlap. It is best to use disease-specific tools like the GAD-7 or Parkinson Anxiety Scale (PAS).